JAK2-mutated ET. Rotunno et al identified a 10-year cumulative incidence of thrombosis of 5.1% vs 14.5% in CALR- vs JAK2-mutated patients, respectively, paralleling the 15-year cumulative thrombosis incidence of 10.5% vs 25.1% identified by Rumi et al. The higher thrombosis rate in JAK2-mutated ET patients may be partly attributable to the hyperviscosity associated with higher hematocrit and leukocyte levels, the latter being a putative risk factor for thrombosis in MPNs. Evaluation of leukocyte and platelet activation, as well as hypercoagulability profiles, will lend further insight into this differential propensity for thrombosis.

The effect of mutational status on the clinical course of ET was evaluated in both studies and was also compared with PV. Although ET patients carrying a CALR mutation exhibited a better overall survival than PV patients, a nonsignificant trend or no difference in survival was found between CALR and JAK2-mutated ET patients. In contrast, a significant difference (P = .04) was observed in 10-year overall survival between these ET subgroups by Klampf et al. The 15-year cumulative incidence of secondary myelofibrosis was similar between CALR- and JAK2-mutated ET and PV, but evolution to leukemia was lower for CALR-mutated ET patients compared with the other groups. Whereas a significant fraction of JAK2-mutated ET patients progressed to PV, none with a CALR mutation did so. Consistent with prior data, the median JAK2 mutant allele burden was higher in ET patients who progressed to PV, as well as in post-PV/ET MF compared with the initial MPN. These data reinforce that PV and JAK2-mutated ET form a continuum wherein phenotype and natural history are substantially influenced by JAK2 allele burden.

While investigators decipher how CALR mutations contribute to MPN pathogenesis, it is clear that CALR will be quickly assimilated by World Health Organization diagnostic criteria for ET and PMF. Less clear is whether CALR mutation status will provide independent prognostic utility in scoring systems used to estimate vascular risk and survival. Also, the effect of CALR mutant allele burden on clinical correlates remains untested. Looking forward, these observational studies provide a framework for assessing whether conventional therapies used broadly for ET (eg, aspirin for low-risk patients and hydroxyurea for high-risk individuals) are also appropriate for CALR-mutated patients who may exhibit lower-risk features.

Conflict-of-interest disclosure: J.G. receives funding for administration of clinical trials, serves on an advisory board, and receives honoraria from Incyte, Inc. The remaining author declares no competing financial interests.

REFERENCES

© 2014 by The American Society of Hematology

---

**Comment on Poli et al, page 1564**

**BuPping iron with modified heparins**

Jodie L. Babitt1 and Herbert Y. Lin1

1. MASSACHUSETTS GENERAL HOSPITAL

In this issue of Blood, Poli et al demonstrate that heparin analogs engineered to minimize their anticoagulant properties can potently downregulate hepcidin production in vitro and in vivo, and may potentially be used to treat the anemia of inflammation.

Hepcidin is the key iron hormone that regulates iron availability from 3 main sources: dietary absorption, red blood cell recycling, and body iron stores. H Hepcidin acts by inducing degradation of the principal iron exporter ferroportin, thereby blocking iron release into the bloodstream and leading to iron sequestration in enterocytes, macrophages, and hepatocytes. Increases in iron levels stimulate hepcidin production to “turn off” further iron release into the circulation and to prevent iron excess. Inflammation also stimulates hepcidin production to limit iron accessibility to infectious organisms. Alternatively, when erythropoiesis is stimulated by anemia or hypoxia, hepcidin production is inhibited to “turn on” iron release into the circulation to support red blood cell production. Diseases of dysregulated hepcidin include hemochromatosis, in which too little hepcidin leads to iron overload, and the anemia of inflammation (also called anemia of chronic disease), in which too much hepcidin leads to iron-restricted erythropoiesis.

Hepcidin is mainly secreted by hepatocytes in the liver, where its expression is controlled by a variety of signals. One central signaling pathway that controls hepcidin production is the bone morphogenetic protein (BMP)-sons of mothers against decapentaplegic (SMAD) signaling pathway through the coreceptor hemojuvelin and the ligand BMP6. This pathway is not only essential for hepcidin regulation by iron, but its activity is also...
required for hepcidin activation by inflammatory cytokines via the signal transducer and activator of transcription 3 signaling pathway.5

The central function of the hepcidin-ferroportin axis in iron homeostasis regulation makes this pathway an attractive therapeutic target.9 Indeed, previous studies have demonstrated that inhibiting hepcidin production or activity with a soluble hemojuvelin fusion protein, a small-molecule production or activity with a soluble hemojuvelin on the hepatocyte membrane. Blockade of this active signaling complex inhibits phosphorylation of intracellular SMAD 1, SMAD5, and SMAD6 proteins (SMAD1/5/6) and their interaction with SMAD4, thereby blunting hepcidin transcription.

In 2011, Poli et al discovered that heparins can block hepcidin production by inhibiting BMP-SMAD signaling, presumably by binding and sequestering BMP ligands.9 However, heparin’s anticoagulant properties pose an obvious limitation for its potential therapeutic application in the treatment of iron disorders. In the current study, Poli et al demonstrate for the first time that glycol-split, nonanticoagulant heparins (gs-heparins) still retain the ability to inhibit the BMP signaling pathway and prevent hepcidin production in the liver both in vitro and in vivo (see figure). Gs-heparin derivatives RO-82 and RO-68 appear to have the most potent activity in inhibiting hepcidin expression, with a 50% inhibition/inhibitory concentration of ~120 ng/mL. The authors also show that these gs-heparins abolish hepcidin induction caused by the inflammatory cytokines interleukin-6 and Oncostatin M. Moreover, the gs-heparins blunt hepcidin induction and ameliorate hypoferremia in a lipopolysaccharide model of inflammation. Although these gs-heparins had no effect on the progression of anemia induced by a heat-killed Brucella abortus model, they did modestly improve recovery from the anemia.

The majority of the antithrombin activity of gs-heparins was attributed to their interference with the BMP-SMAD signaling pathway. This is consistent with the BMP-SMAD–dependent nature of interleukin–6–mediated induction of hepcidin expression.5

However, a number of questions remain. First, the mechanism of action of modified heparins in inhibiting hepcidin in the context of inflammation may not be completely worked out. For example, 1 of the nonanticoagulant heparins (NAc-91) had minimal impact on the BMP-SMAD signaling pathway at lower concentrations, but still inhibited hepcidin synthesis. Moreover, the nonanticoagulant heparins also appear to inhibit lipopolysaccharide induction of other inflammatory markers, including Socs3 and Crp. Indeed, it has been previously described that heparins possess anti-inflammatory activities.10 Together, these data suggest that there may be additional BMP-independent mechanisms by which heparins inhibit hepcidin expression, possibly related to their proposed anti-inflammatory activities. Moreover, issues regarding the pharmacokinetics and pharmacodynamics of the gs-heparins remain to be elucidated, as do their long-term safety profile. Obvious off-target effects of concern include residual anticoagulant activities, general inhibition of the BMP-SMAD signaling pathway, and additional nonanticoagulant activities including interaction with other growth factors.10 Nevertheless, this work shows that gs-heparins are a new class of candidate therapeutics for targeting the relevant signaling pathways that regulate hepcidin to treat the anemia of inflammation.

REFERENCES

© 2014 by The American Society of Hematology
BuMPing iron with modified heparins

Jodie L. Babitt and Herbert Y. Lin